Biology and Treatment of High-Risk CLL: Significance of Complex Karyotype

Thomas Chatzikonstantinou; Christos Demosthenous; Panagiotis Baliakas; Panagiotis Baliakas

doi:10.3389/fonc.2021.788761

Frontiers in Oncology (Nov 2021)

Biology and Treatment of High-Risk CLL: Significance of Complex Karyotype

Thomas Chatzikonstantinou,
Christos Demosthenous,
Panagiotis Baliakas,
Panagiotis Baliakas

Affiliations

Thomas Chatzikonstantinou: Hematology Department—Bone Marrow Transplantation (BMT) Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
Christos Demosthenous: Hematology Department—Bone Marrow Transplantation (BMT) Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
Panagiotis Baliakas: Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
Panagiotis Baliakas: Department of Clinical Genetics, Uppsala University Hospital, Uppsala, Sweden

DOI: https://doi.org/10.3389/fonc.2021.788761
Journal volume & issue: Vol. 11

Abstract

Read online

Several reports highlight the clinical significance of cytogenetic complexity, namely, complex karyotype (CK) identified though the performance of chromosome banding analysis (CBA) in chronic lymphocytic leukemia. Indeed, apart from a number of studies underscoring the prognostic and predictive value of CK in the chemo(immune)therapy era, mounting evidence suggests that CK could serve as an independent prognosticator and predictor even in patients treated with novel agents. In the present review, we provide an overview of the current knowledge regarding the clinical impact of CK in CLL, touching upon open issues related to the incorporation of CK in the clinical setting.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords